Alyeska Investment Group
RGC icon

Alyeska Investment Group’s Regencell Bioscience RGC Stock Holding History

Alyeska Investment Group’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
+416,261
New +$10M 0.01% 555

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

Alyeska Investment Group's RGC Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Regencell Bioscience (RGC) in Q2 2026: 416,261 shares worth $2.54M. The stake represents 0.01% of the portfolio and ranks #555 among its holdings.

35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Alyeska Investment Group held 416,261 shares of Regencell Bioscience worth $2.54M as of Q2 2026.
  • Regencell Bioscience was a new Alyeska Investment Group position in Q2 2026.
  • Regencell Bioscience made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #555 holding.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.